Basin Energy (BSN:AU) has announced Queensland Uranium and Rare Earth Acquisition Completed
Download the PDF here.
This post appeared first on investingnews.com
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.
Read on to learn what’s been driving these Canadian biotech firms.
1. Eupraxia Pharmaceuticals (TSX:EPRX)
Year-on-year gain: 141.23 percent
Market cap: C$410.85 million
Share price: C$8.25
Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues.
The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well.
Eupraxia added EP-104GI to its pipeline through its acquisition of EpiPharma Therapeutics in late 2023. The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b/2a trial cohorts.
In July, Eupraxia dosed its first patient after advancing its investigation to Phase 2b trials based on safety and efficacy data from the earlier Phase 2a patient cohorts. Top-line results from the Phase 2b study are anticipated in the second half of 2026.
In September, the company shared data from the highest-dose cohort of the still ongoing Phase 1b/2a trials, reporting that the group saw the largest improvements so far.
2. Bright Minds Biosciences (CSE:DRUG)
Year-on-year gain: 103.17 percent
Market cap: C$683.67 million
Share price: C$92.95
Bright Minds Biosciences is developing novel serotonin agonists targeting neurocircuit abnormalities linked to neuropsychiatric disorders and epilepsy, designing next-generation treatments that aim to retain the therapeutic benefits of psychedelics while minimizing side effects.
Its lead candidate, BMB-101, a selective 5-HT2C receptor agonist, has shown encouraging preclinical efficacy by stopping seizures in an epilepsy mouse model, evaluated jointly with Firefly Neuroscience (NASDAQ:AIFF).
The company’s stock surged nearly 1,500 percent in October 2024 following H. Lundbeck’s acquisition announcement of a competitor focused on similar targets. Strengthening its epilepsy expertise, Bright Minds expanded its scientific advisory board in early 2025 by adding five leaders in the field.
Ongoing clinical progress and strategic growth initiatives position Bright Minds as a promising contender in the neuropsychiatric treatment landscape.
3. Hemostemix (TSXV:HEM)
Year-on-year gain: 31.25 percent
Market cap: C$18.40 million
Share price: C$0.11
Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, meaning the treatments use a patient’s own cells to theoretically enhance safety and efficacy.
Its main product, ACP-01, is an autologous cell therapy designed to promote tissue repair and regeneration in areas affected by diseases, including a range of heart diseases.
The company announced its first advanced sales orders for ACP-01 in Q1 2025 and has been working to expand internationally and attract new investment.
Hemostemix secured the regulatory green light for commercial sales in Florida after the state passed Senate Bill 1768. The bill creates a framework in which healthcare providers can administer stem cell therapies that had not yet been approved by the US Food and Drug Administration (FDA) but meet the bill’s guidelines.
The company now offers commercial ACP-01 treatments for ischemic pain in the state under the name VesCell, with sales forecasted to reach C$22.5 million in 2026. Operational plans target cash flow positivity by Q4 2026, supported by a growing physician network and commercial pipeline.
Additionally, Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia.
4. NervGen (TSXV:NGEN)
Year-on-year gain: 79.92 percent
Market cap: C$300.97 million
Share price: C$4.39
NervGen is a clinical-stage Canadian biotechnology company that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease.
The company’s core technology targets a mechanism that hinders nervous system repair. When the nervous system is damaged, chondroitin sulfate proteoglycans (CSPG) form a “scar.” Initially, CSPGs help contain damage, but their long-term interaction with the PTPσ receptor inhibits repair.
NervGen’s lead drug candidate, NVG-291, is designed to relieve these inhibitory effects to promote nervous system repair. It received fast-track designation from the US FDA.
NervGen is advancing NVG-291 in a Phase 1b/2a clinical trial for spinal cord injury (SCI) and reported positive data from the chronic cohort in June.
NVG-300, a newer preclinical candidate, is being evaluated for ischemic stroke and SCI.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Astral Resources (AAR:AU) has announced Feysville Land Use Agreement Signed With Marlinyu Ghoorlie
Download the PDF here.
This post appeared first on investingnews.com
In a ground-breaking Bitcoin news development today, financial giant JPMorgan on Friday said it plans to allow its institutional and high-net-worth clients to use BTC and ETH directly as collateral for loans. This comes as traditional financial giants such as BlackRock, Morgan Stanley, and Goldman Sachs enter the crypto market amid a pro-crypto regulatory landscape.
The post Breaking: JPMorgan Enables Institutions to Use Bitcoin, Ethereum as Collateral appeared first on CoinGape.
The Sui price has recently drawn investor interest after rebounding from a key demand zone, signaling renewed strength across the market. Meanwhile, the blockchain has achieved historic milestones, with its Total Value Locked (TVL) and monthly DEX volume reaching all-time highs. This surge in activity showcases expanding ecosystem participation and underscores Sui’s growing relevance within
The post SUI Price Prediction as TVL and Monthly DEX Volume Hit All-Time Highs- What’s Next? appeared first on CoinGape.
The U.S. CPI inflation data came in below expectations, increasing the odds of two more rate cuts this year. Bitcoin rose on the back of the data release, seeing as the Fed could make another rate cut at the upcoming FOMC meeting next week. CPI Inflation Data Rises To 3% Year-On-Year, Bitcoin Surges Bureau of
The post Breaking: U.S. CPI Comes In Lower Than Expectations, Bitcoin Rises appeared first on CoinGape.
DraftKings:- DraftKings is making a calculated pivot into prediction markets after acquiring CFTC-registered Railbird Technologies. This is a move the sports-betting giant said will power a new “DraftKings Predictions” app for trading event contracts across finance, culture and entertainment. The acquisition, announced Oct. 21, lets DraftKings expand beyond traditional sports wagering into a rapidly growing
The post Is DraftKings Facing Threat from Prediction Markets? What’s behind the Move appeared first on CoinGape.
BitMine’s Tom Lee and veteran trader Peter Brandt have both warned of a potential 50% correction in BTC. This has led to speculation of a possible Bitcoin crash despite record inflows into its ETFs. Tom Lee Warns Bitcoin Could Still Halve in Value In a recent interview with crypto investor Anthony Pompliano, Tom Lee, chairman
The post Bitcoin Crash Incoming? Tom Lee Backs Peter Brandt’s 50% Decline Prediction Despite Strong ETF Inflows appeared first on CoinGape.
The American cattle ranching industry is blasting President Donald Trump’s proposal to purchase beef from Argentina in an effort to lower supermarket beef prices.
“This plan only creates chaos at a critical time of the year for American cattle producers, while doing nothing to lower grocery store prices,” Colin Woodall, CEO of the National Cattlemen’s Beef Association, said in a statement Monday.
Wyoming-based cattle operation Meriwether Farms addressed Trump directly in a social media post Monday.
“We love you and support you — but your suggestion to buy beef from Argentina to stabilize beef prices would be an absolute betrayal to the American cattle rancher,” the farm wrote on X.
By midday Tuesday, the post had already received 4 million views. A representative for Meriwether Farms did not immediately respond to a request for comment.
Trump floated purchasing beef from the South American nation Sunday aboard Air Force One to push down U.S. beef prices by increasing the overall supply.
‘We would buy some beef from Argentina,’ he told reporters, ‘If we do that, that will bring our beef prices down.’
Beef prices have hit record highs this year, according to data from the Bureau of Labor Statistics, fueled in part by depleted herd counts and steady demand from U.S. consumers.
This post appeared first on NBC NEWS
A group that includes activist investor Jana Partners and NFL player Travis Kelce says it has accumulated one of the largest ownership stakes in Six Flags Entertainment and intends to press the company’s leadership on ways to improve the struggling amusement park operator’s business.
Jana said Tuesday that the investor group now owns an economic interest of approximately 9% in Six Flags. The group plans to ‘engage’ with Six Flags’ management and board of directors to discuss ways to enhance shareholder value and improve visitors’ experience.
Shares in the Charlotte, North Carolina-based Six Flags surged 17.7% on the news. The shares added another 5.1% gain in after-hours trading. Even with Tuesday’s rally, the company’s shares are down about 47% so far this year.
Six Flags reported a loss of $319.4 million for the first half of the year. The company said attendance fell 9% in the three months that ended June 29, due partly to bad weather and a ‘challenged consumer’ in most of the markets it operates in.
The investor group also includes consumer executive Glenn Murphy and technology executive Dave Habiger.
Kelce, tight end for the Kansas City Chiefs, said in a statement that he grew up going to Six Flags amusement parks.
‘The chance to help make Six Flags special for the next generation is one I couldn’t pass up,’ he said.
This post appeared first on NBC NEWS